Internal Medicine, Endocrinology, Diabetes, & Metabolism · San Antonio, TX
NPI
1043494826
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
5
Medicare group memberships
Hospitals
0
Hospital affiliations
7355 Barlite Blvd Ste 401
San Antonio, TX, 78224
Phone (210) 222-0333
Groups this clinician bills Medicare through
Medicare paid, 2024
$8,350
198 services
Medicare patients, 2024
58
Average age 72
Drug cost, 2024
$5.0M
5,047 prescriptions
Company payments, 2025
$411
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jennifer M Argumedo was code 99214 (office e&m - established), 61 times for 39 patients. In total Jennifer M Argumedo billed 198 services in 10 codes, and Medicare paid $8,350.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-09-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 61 | 39 | $81.49 | $4,971 |
| 82947 Clinical Chemistry | Office | 48 | 33 | $3.77 | $181 |
| 83036 Blood Count | Office | 35 | 27 | $9.52 | $333 |
By year: 2022 $12K for 247 services; 2023 $11K for 258 services; 2024 $8,350 for 198 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82947 Clinical Chemistry | 48 | 33 | $3.77 | $181 |
| 83036 Blood Count | 35 | 27 | $9.52 | $333 |
Medicare prescription drug claims, 2024
In 2024, the drug Jennifer M Argumedo prescribed most often to Medicare patients was Ozempic (Semaglutide), with 489 prescriptions and refills. In total Jennifer M Argumedo wrote 5,047 Medicare prescriptions that cost $5.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 489 | 642 | 103 | $620K |
| Mounjaro Tirzepatide | 442 | 568 | 103 | $615K |
| Trulicity Dulaglutide | 423 | 828 | 129 | $846K |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | 390 | 782 | 107 | $506K |
| Levothyroxine Sodium Generic | 234 | 713 | 75 | $3,635 |
| Lyumjev Kwikpen U-100 Insulin Lispro-Aabc | 232 | 438 | 84 | $207K |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 211 | 325 | 52 | $213K |
| Pioglitazone Hcl Generic | 192 | 579 | 70 | $2,104 |
| Jardiance Empagliflozin | 192 | 493 | 65 | $294K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 180 | 528 | 86 | $21K |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | 172 | 438 | 72 | $98K |
| Januvia Sitagliptin Phosphate | 148 | 305 | 38 | $170K |
| Tresiba Flextouch U-200 Insulin Degludec | 129 | 273 | 48 | $142K |
| Metformin Hcl Er Metformin Hcl | 129 | 406 | 52 | $1,130 |
| Metformin Hcl Generic | 124 | 360 | 45 | $1,544 |
Brand drugs: 3,538 claims; generic drugs: 1,127 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jennifer M Argumedo $411 ($411 in general payments such as food, travel and fees) from 3 companies. The largest payer was Dexcom, Inc. with $219.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.